Scholar Rock

Scholar Rock

Yahoo Finance • 5 days ago

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same site that supported Septemb... Full story

Yahoo Finance • 28 days ago

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research. Street commentary around the Isembyld app... Full story

Yahoo Finance • 28 days ago

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

[Wall Street street sign in Manhattan financial district] Alexey_Fedoren Scholar Rock (SRRK [https://seekingalpha.com/symbol/SRRK]) shares continued to tumble on Tuesday as Barclays downgraded the Massachusetts-area biotech despite last w... Full story

Yahoo Finance • 29 days ago

Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says

Scholar Rock Holding (SRRK) won early regulatory approval of Isembyld to treat spinal muscular atrop PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 29 days ago

Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy

Medical researcher in gloves using a tablet ©Adobe Stock Images Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9.1% in pre-market trading to $60.45 after the US Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) for th... Full story

Yahoo Finance • 29 days ago

Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump

Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks f... Full story

Yahoo Finance • 2 months ago

Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Scholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest v... Full story

Yahoo Finance • 2 months ago

Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility

Scholar Rock (SRRK) said Friday that, under guidance from the FDA, it has removed Novo Nordisk's (NV PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA); FDA review o... Full story

Yahoo Finance • 2 months ago

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a... Full story

Yahoo Finance • 2 months ago

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biolog... Full story

Yahoo Finance • 2 months ago

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (O... Full story

Yahoo Finance • 2 months ago

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Pres... Full story

Yahoo Finance • 3 months ago

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareh... Full story

Yahoo Finance • 3 months ago

Texas Stock Exchange live in Dallas. Y'all Street takes on Wall Street

Move over, New York and Nasdaq — there's a new stock exchange in Texas. On Monday, the Texas Stock Exchange (TXSE) in Dallas went live — but only for members — as it began test trading of designated securities with live trading set to sta... Full story

Yahoo Finance • 4 months ago

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

CAMBRIDGE, Mass., June 22, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and d... Full story

Yahoo Finance • 5 months ago

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CAMBRIDGE, Mass., May 26, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and de... Full story

Yahoo Finance • 5 months ago

A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. What recent returns say about Scholar Rock Holding (SRRK) Scholar Rock Holding (SRRK) stock has been relatively mixed... Full story

Yahoo Finance • 5 months ago

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date Accepted apitegromab BLA includ... Full story

Yahoo Finance • 6 months ago

Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal?

On March 31, 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, now incorporating both the Novo Nordisk-owned Catalent Indiana site and a second U.S.-bas... Full story